arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Editas Medicine, Inc.

EDIT
$2.87 ▼ -0.03 (-1.20%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
47 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Editas Medicine, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $280.9M
Dividend Yield
Revenue Growth -39.2%
Op. Margin None
ROIC -38.3%
FCF / Share $-0.24
Trailing P/E
Price / Book 63.7x
FCF Yield
Debt / Equity 10.70
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.83M
↓ -39.2%
Net Income Profit after all expenses
$-24.98M
↑ +67.2%
Operating Margin Operating profit as % of sales
-31.3%
↑ +90.4% 0th
FCF / Share Free cash flow per share
$-0.24
↑ +59.0%
Long-Term Debt Long-term obligations
$47.18M
↓ -12.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Financial Health
17
Cash Quality
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters